Trial Profile

An Open-label, Multicenter Phase I Clinical Study of SHR-7782 Injection in the Treatment of Advanced Malignant Cancer

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 10 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SHR 7782 (Primary)
Indications Solid tumours
Focus Adverse reactions
Sponsors Suzhou Suncadia Biopharmaceuticals

Most Recent Events

22 Sep 2025 Status changed from not yet recruiting to recruiting.
25 Aug 2025 New trial record
15 Aug 2025 According to a Suzhou Shengdia Biopharmaceutical media release, the company announced that it has received the approval from the State Food and Drug Administration (hereinafter referred to as the SFDA) The Drug Clinical Trial Approval Notice for SHR-7782 Injection was issued and clinical trials will be carried out in the near future.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com